BioMarin Pharmaceuticals BMRN Research and early pipeline — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's research and early pipeline — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's research and early pipeline — R&D?
- BioMarin Pharmaceuticals (BMRN) reported research and early pipeline — R&D of $87.29M in Q1 2026.
- How has BioMarin Pharmaceuticals's research and early pipeline — R&D changed year-over-year?
- BioMarin Pharmaceuticals's research and early pipeline — R&D decreased by 3.5% year-over-year, from $90.47M to $87.29M.
- What is the long-term trend for BioMarin Pharmaceuticals's research and early pipeline — R&D?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's research and early pipeline — R&D has grown at a 6.9% compound annual growth rate (CAGR), from $313.92M to $383.71M.
- What does research and early pipeline — R&D mean?
- The total investment in discovering and testing new potential drug candidates in the early stages of development.
- How do you interpret research and early pipeline — R&D?
- An increase suggests a commitment to expanding the pipeline and future growth potential, while a decrease may indicate a strategic shift toward cost-efficiency or a focus on late-stage assets.
- How does research and early pipeline — R&D compare across companies?
- Peers in the biotechnology sector typically report this as a component of total R&D expenses, often benchmarked as a percentage of total revenue or as a proportion of the total R&D budget to gauge innovation intensity.